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Intracellular signalling by NO/cGMP/cGMP-dependent
protein kinase type I (cGKI) regulates various physiologi-
cal processes including smooth muscle contractility and
platelet aggregation. An important mediator of this signal-
ling cascade is the inositol 1,4,5-trisphosphate receptor I
(IP3RI) associated protein cGMP kinase substrate (IRAG).
This protein forms a trimeric complex together with the
cGMP kinase Iβ (cGKIβ) and the IP3RI. Targeted deletion
of exon 12 of IRAG coding for the N-terminal part of the
coiled-coil domain disrupted in vivo the IRAG-IP3RI inter-
action. The resulting IRAG∆12/∆12 mice showed an
increased mortality and a severely reduced gastrointesti-
nal motility. The relaxation of hormone-contracted aortic
and longitudinal colonic smooth muscle by cGMP was
abolished in IRAG∆12/∆12 mice, whereas cAMP-mediated
relaxation was not altered. In contrast to WT mice, nore-
pinephrine-induced increases in [Ca2+]i were not reduced
by cGMP in aortic smooth muscle cells from IRAG∆12/∆12
mice. These data suggest, that IRAG is involved in the
cGMP-dependent decrease of [Ca2+]i in vivo and is essen-
tial for cGMP-dependent relaxation of hormone-induced
vascular and colonic muscle contraction. However,
cGMP-mediated relaxation of small intestinal smooth
muscles was only partially affected in IRAG∆12/∆12 mice
suggesting tissue specific selectivity of cGKI mechanisms.
In addition, IRAG is highly expressed in platelets. To study
the effect of IRAG signalling in platelets, we analysed the
aggregation of IRAG∆12/∆12 platelets. Nitric oxide and the
cGMP analogue 8-pCPT-cGMP did not inhibit the aggre-
gation of IRAG∆12/∆12 platelets in contrast to wild type
platelets, whereas the shape change of platelets was not
affected in both mutant and wild type platelets. Further-
more, tail bleeding was abbreviated in IRAG∆12/∆12 mice
suggesting a defect in the regulation of coagulation in vivo.
Therefore, cGKI/IRAG/IP3RI signalling might be crucial
for the NO/cGMP-dependent inhibition of platelet aggre-
gation.
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